New drug cocktail aims to tackle Hard-to-Treat stomach and esophageal cancers
NCT ID NCT05187182
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new targeted drug called CA-4948 combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study will enroll 42 participants and will first find the safest dose of CA-4948, then test it in two groups: one with HER2-negative cancer and one with HER2-positive cancer (adding trastuzumab). The main goals are to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CA-4948 (a targeted drug) combined with chemotherapy (FOLFOX), immunotherapy (nivolumab or pembrolizumab), and possibly trastuzumab
- What this could lead to
- If successful, this could point toward a new combination treatment for advanced stomach and esophageal cancers that are hard to treat.
- What could go wrong
- This is an early Phase I trial with only 42 people, so safety and dosing are still being figured out. The combination may cause significant side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?